Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABSTU:5JE -3.91%55 OCF Margin % is 23.04% as of Jun. 2026, which is 4508% above its 10-year median of 0.50. GuruFocus rates STU:5JE with a GF Score™ of 55/100 and a GF Value™ of €2.66 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bactiguard Holding AB ranks better than 51.53% on this metric.
The historical rank and industry rank for Bactiguard Holding AB's OCF Margin % or its related term are showing as below:
STU:5JE'
s OCF Margin % Range Over the Past 10 Years
Min: -25.65 Med: 0.5 Max: 29.18
Current: 6.73
During the past 13 years, the highest OCF Margin % of Bactiguard Holding AB was 29.18%. The lowest was -25.65%. And the median was 0.50%.
STU:5JE's OCF Margin % is ranked better than 51.53% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.82
vs STU:5JE: 6.73
Bactiguard Holding AB OCF Margin % Related Terms
Bactiguard Holding AB OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bactiguard Holding AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (STU:5JE) has a OCF Margin % of 23.04% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bactiguard Holding AB and its competitors. This is 4508% above median its historical median of 0.50. According to the industry distribution chart, Bactiguard Holding AB ranks #395 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 48.5%.
Is Bactiguard Holding AB's OCF Margin % too high?
Bactiguard Holding AB's current OCF Margin % of 23.04% is 4508% above median its 10-year median of 0.50. The Medical Devices & Instruments industry median OCF Margin % is 5.82. Bactiguard Holding AB's value of 23.04% is 295.9% above this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #395 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #395 out of 815 companies for OCF Margin %. This puts Bactiguard Holding AB in the upper half of its industry. The industry median OCF Margin % is 5.82. Bactiguard Holding AB's value of 23.04% is 295.9% above this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 5.82, Bactiguard Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.82, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current OCF Margin % of 23.04% is 295.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current OCF Margin % is 23.04%, which is 4508% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bactiguard Holding AB (STU:5JE) is currently considered Possible Value Trap. The stock's GF Value™ is €2.66, compared to a current price of €1.35 — trading 49.2% below its estimated fair value. The current OCF Margin % is 23.04%, which is 4508% above median its 10-year median of 0.50 and 295.9% above the Medical Devices & Instruments industry median of 5.82. Bactiguard Holding AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bactiguard Holding AB (STU:5JE), the current OCF Margin % is 23.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (STU:5JE) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of €1.35 is trading 49.2% below its estimated GF Value™ of €2.66.
GuruFocus considers Bactiguard Holding AB to be Possible Value Trap.
Key valuation signals for STU:5JE:
OCF Margin %: 23.04% (4508% above median its 10-year median of 0.50)
GF Value™: €2.66 vs. price of €1.35 (49.2% below fair value)
Industry Position: 295.9% above the Medical Devices & Instruments median (#395 of 815)
No single metric tells the full story. See the STU:5JE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
55GF Score
Get the complete analysis for STU:5JE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5JE has been successfully added to your 
